Loading...
XJPX3349
Market cap3.32bUSD
Dec 25, Last price  
6,479.00JPY
1D
-0.12%
1Q
-9.23%
Jan 2017
-39.01%
Name

Cosmos Pharmaceutical Corp

Chart & Performance

D1W1MN
XJPX:3349 chart
P/E
21.00
P/S
0.53
EPS
308.54
Div Yield, %
0.91%
Shrs. gr., 5y
14.88%
Rev. gr., 5y
9.57%
Revenues
964.99b
+16.59%
78,651,000,000105,046,000,000125,846,000,000148,244,000,000177,756,000,000205,387,000,000237,174,000,000279,021,000,000329,313,000,000371,825,000,000408,466,000,000447,273,000,000502,732,000,000557,999,000,000611,137,000,000684,403,000,000726,424,000,000755,414,000,000827,697,000,000964,989,000,000
Net income
24.45b
+2.76%
1,259,000,0001,944,000,0002,299,000,0002,173,000,0002,841,000,0004,712,000,0005,737,000,0007,737,000,0009,396,000,00010,600,000,00011,694,000,00012,435,000,00018,215,000,00017,633,000,00019,185,000,00021,435,000,00027,156,000,00023,155,000,00023,797,000,00024,454,000,000
CFO
55.18b
+1.36%
3,505,000,0003,298,000,0002,807,000,0007,694,000,00010,083,000,0007,734,000,00014,166,000,00016,095,000,00018,765,000,00025,962,000,00019,454,000,00030,986,000,00036,938,000,00032,586,000,00034,379,000,00065,461,000,00027,875,000,00032,194,000,00054,434,000,00055,175,000,000
Dividend
May 29, 20250 JPY/sh
Earnings
Jan 10, 2025

Profile

COSMOS Pharmaceutical Corporation operates a chain of drug stores in Japan. As of May 31, 2022, the company operated 1,244 stores in the Kanto, Chubu, Kansai, Chugoku, Shikoku, and Kyushu regions. The company was incorporated in 1983 and is headquartered in Fukuoka, Japan.
URL
https://www.cosmospc.co.jp/
IPO date
Nov 11, 2004
Employees
5,290
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑052015‑05
Income
Revenues
964,989,000
16.59%
827,697,000
9.57%
755,414,000
3.99%
Cost of revenue
778,611,000
660,755,000
605,725,000
Unusual Expense (Income)
NOPBT
186,378,000
166,942,000
149,689,000
NOPBT Margin
19.31%
20.17%
19.82%
Operating Taxes
9,265,000
8,975,000
9,892,000
Tax Rate
4.97%
5.38%
6.61%
NOPAT
177,113,000
157,967,000
139,797,000
Net income
24,454,000
2.76%
23,797,000
2.77%
23,155,000
-14.73%
Dividends
(4,659,000)
(3,266,000)
(3,266,000)
Dividend yield
0.46%
0.62%
0.68%
Proceeds from repurchase of equity
8,142,000
(1,468,000)
BB yield
-1.55%
0.30%
Debt
Debt current
6,512,000
4,485,000
3,056,000
Long-term debt
33,648,000
19,158,000
11,383,000
Deferred revenue
(442,000)
(451,000)
Other long-term liabilities
4,325,000
4,126,000
4,125,000
Net debt
(16,527,000)
(43,886,000)
(42,818,000)
Cash flow
Cash from operating activities
55,175,000
54,434,000
32,194,000
CAPEX
(55,810,000)
(46,636,000)
(43,497,000)
Cash from investing activities
(57,329,000)
(49,113,000)
(43,717,000)
Cash from financing activities
8,527,000
3,245,000
(6,222,000)
FCF
152,299,000
129,294,000
108,112,000
Balance
Cash
52,301,000
45,928,000
37,362,000
Long term investments
4,386,000
21,601,000
19,895,000
Excess cash
8,437,550
26,144,150
19,486,300
Stockholders' equity
226,564,000
417,734,000
376,638,000
Invested Capital
261,389,450
200,536,850
179,111,700
ROIC
76.68%
83.22%
88.59%
ROCE
69.07%
73.50%
75.20%
EV
Common stock shares outstanding
79,240
39,599
39,599
Price
12,690.00
-4.30%
13,260.00
8.69%
12,200.00
-19.89%
Market cap
1,005,551,362
91.50%
525,081,056
8.69%
483,107,898
-19.90%
EV
989,024,362
692,226,056
630,790,898
EBITDA
206,302,000
184,310,000
164,799,000
EV/EBITDA
4.79
3.76
3.83
Interest
99,000
51,000
52,000
Interest/NOPBT
0.05%
0.03%
0.03%